A Research Study Looking Into How NNC0662-0419 Works With Birth Control Pills and Emptying of the Stomach in Women Not Able to Become Pregnant With Excess Body Weight

Part of paid clinical trials in Overland Park, Kansas.

Sponsor
Novo Nordisk A/S
Study ID
NCT07525791
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 64 Years
Healthy Volunteers
Accepted

Interventions

  • NNC0662-0419 — DRUG
    Once-weekly subcutaneous NNC0662-0419 will be administered using a pen injector
  • Oral contraceptive — DRUG
    An oral contraceptive Altavera \[levonorgestrel (LN) 0.15 milligram (mg) and ethinyl estradiol (EE) 0.03 mg\] will be administered orally.
  • Acetaminophen — DRUG
    A single dose of acetaminophen will be administered orally.

Study Details

The purpose of this clinical study is to find out if NNC0662-0419 is safe and effective to be taken together with other medicines, like birth control pills, and emptying of the stomach in women not able to become pregnant living with overweight or obesity. There are 3 study treatments in this study, participants will get all of the treatments, NNC0662-0419 the treatment being tested, Altavera a type of birth control pill, Acetaminophen a common type of mild painkiller.

Key Dates

Start date
Apr 7, 2026
Status verified
Apr 2026
Primary completion
Apr 8, 2027
Completion
May 4, 2027

Study Design

Enrollment
45 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: NNC0662-0419 with oral contraceptive (Altavera) and acetaminophen
    Participants will receive once-weekly subcutaneous NNC0662-0419, with multiple doses administered over the treatment period. An oral contraceptive will be administered as a number of tablets per treatment period, with dosing conducted under supervised conditions. In addition, a single dose of acetaminophen will be administered as part of a standardized meal during treatment period.

Primary Outcome Measure

Area under curve (AUC) 0-24 h, EE, steady state (SS): The area under the EE plasma concentration-time curve (pre-dose to 24 hours post-dose) [ Time Frame: Day 8 and 1 day after last NNC0662-0419 dose ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Altasciences Clinical Kansas, Inc.Overland ParkKansas66212-

Find similar trials in Overland Park, KS

By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Altasciences Clinical Kansas, Inc.· Overland Park, KS

Related Studies